等待开盘 08-21 09:30:00 美东时间
-0.740
-0.68%
Pliant Therapeutics has halted development of bexotegrast in idiopathic pulmonary fibrosis (IPF) following a safety and efficacy analysis. The company continues Phase 1 trials of PLN-101095 in solid tumors, expecting data by year-end. Restructuring efforts to reduce costs have largely been completed, with decreases in R&D and general expenses. As of June 2025, the company held $264.4 million in cash. Pliant remains focused on advancing integrin-b...
08-07 20:05
Planet Fitness shares are trading lower following the release of its Q2 financi...
08-06 23:44
Planet Fitness (NYSE:PLNT) raises FY2025 sales outlook from $1.30 billion to $1.43 billion vs $1.30 billion estimate.
08-06 18:36
Planet Fitness (NYSE:PLNT) reported quarterly earnings of $0.86 per share which beat the analyst consensus estimate of $0.79 by 9.41 percent. This is a 21.13 percent increase over earnings of $0.71 per share from the
08-06 18:32
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
Planet Fitness (NYSE:PLNT) is preparing to release its quarterly earnings on We...
08-06 01:02
An appeals court has struck down the Federal Trade Commission's "click-to-cancel" rule requiring businesses to make it as easy for consumers to cancel subscriptions as it was to sign up, citing flaws ...
07-09 17:38
Pliant Therapeutics announced the discontinuation of bexotegrast development in idiopathic pulmonary fibrosis (IPF) following unfavorable safety and efficacy results from the BEACON-IPF Phase 2b/3 trial. While the drug showed modest improvements in lung function, it posed increased risks of disease progression and adverse events. The company is focusing on its oncology program, with PLN-101095 entering Phase 1 trials, and leveraging its proprieta...
06-27 20:05
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1140203048973164544.png</p><span style="color:#999999;">编者按:每日追踪华尔街最新评级与目标价,挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Maxim Group:上调Datavault AI(DVLT)评级至"买入",目标价3美元</p> <p>• 蒙特利尔银行:维持DoubleVerify Holdings(DV)"跑赢大市"评级,目标价从25美元升至26
06-13 09:33
Canaccord Genuity analyst Brian McNamara maintains Planet Fitness (NYSE:PLNT) with a Buy and raises the price target from $120 to $126.
06-12 22:27